{"preliminary_commentary":{"by_channel":{"x_thread":46,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04498767\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"rare oligometastatic cancers","name":"OligoRARE","nct_id":"NCT04498767","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=oligorare-nct04498767. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"OligoRARE","arms":[{"description":"Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).\n\nSystemic therapy will be pre-specified based on the standard of care approach for that patient, and it may include cytotoxic, targeted, hormonal, or immunotherapy.","label":"Arm 1: Standard of Care + palliative RT","type":"ACTIVE_COMPARATOR"},{"description":"The experimental arm consists of SBRT (and standard of care systemic therapy). Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \\& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.\n\nPatients treated with prior or concomitant systemic therapy are eligible for this study. Use of chemotherapy regimens, targeted therapy or immunotherapy containing potent enhancers of radiation damage (e.g. gemcitabine, doxorubicin) can be postponed or interrupted for a duration of one month after radiation.","label":"Arm 2: Standard of Care + SBRT","type":"EXPERIMENTAL"}],"collaborators":["Anticancer Fund, Belgium","Rising Tide Foundation"],"completion_date":{"date":"2030-02-01","type":"ESTIMATED"},"conditions":["Gynecologic Cancer","Skin Cancer","Head and Neck Cancer","Sarcoma","Renal Cancer","Bladder Cancer","Upper Urinary Tract Carcinoma","Pancreatic Cancer","Hepatobiliary Cancer","Gastric Cancer","Small Bowel Cancer","Esophageal Cancer","Melanoma","Colon Cancer","Oligometastasis"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Stereotactic body radiotherapy","otherNames":["SBRT"],"type":"RADIATION"},{"name":"Palliative RT","otherNames":[],"type":"RADIATION"}],"last_update":"2024-08-26","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial","overall_status":"RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2028-08-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"7.5 years from first patient in"}],"references":[],"start_date":{"date":"2021-06-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)","url":"https://clinicaltrials.gov/study/NCT04498767"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/oligorare-nct04498767"}